SCHEMBL839587

SCHEMBL839587

Nc1n[c]nc2n[nH]cc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014919 0.68 PDPK1 (0.39) —
Hydrochloric Acid SCHEMBL1741651 0.67 PI4KA (0.44) —
Hydrochloric Acid SCHEMBL14742344 0.67 PI4KA (0.44) —
SCHEMBL95122 0.65 — —
SCHEMBL901559 0.60 — —
Hydrochloric Acid SCHEMBL2247692 0.57 NCF1 (0.39) —
SCHEMBL888386 0.57 MGMT (0.30) —
SCHEMBL19236510 0.56 CYP1A2 (0.49) —
SCHEMBL342514 0.55 ALDH1A1 (0.44) —
SCHEMBL31058760 0.55 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 — — US disclosed
US-8071608-B2 Therapeutic agents ASTRAZENECA AB (SE) 2011-12-06 — — US disclosed
US-8071585-B2 Therapeutic agents ASTRAZENECA AB (SE) 2011-12-06 — — US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 — — EP disclosed
WO-2010116176-A1 PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY ASTRAZENECA AB (SE) 2010-10-14 — — WO disclosed
WO-2010116177-A1 A PYRAZOLO [4,5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY ASTRAZENECA AB (SE) 2010-10-14 — — WO disclosed
US-20100261733-A1 THERAPEUTIC AGENTS 927 ASTRAZENECA AB (SE) 2010-10-14 — — US disclosed
US-20100261704-A1 THERAPEUTIC AGENTS 928 ASTRAZENECA AB (SE) 2010-10-14 — — US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 — — US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 — — WO disclosed
Send feedback